Associate Director, Medical Affairs
Immix Biopharma, Inc.
Los Angeles / Hybrid
- Our 3 Core Values Intelligence
- Integrity
- Initiative
The Associate Director, Medical Affairs will shape the strategy, and execution of a high-impact, scientifically rigorous organization that will shape how our data are understood, how our therapy is used appropriately in clinical practice, and how we engage with the broader medical and scientific community. This role will also be responsible for establishing a strong partnership with Commercial by developing shared strategic imperatives and collaborating on launch readiness.
What You Will Do
- Shape scientific and clinical narrativeDevelop and articulate a clear, evidence-based scientific narrative for NXC-201, grounded in deep understanding of the data and disease landscape
- Lead scientific exchange with key opinion leaders, investigators, academic institutions and patient advocacy groups
- Shape publication strategy, congress activity, and data dissemination
Drive integrated evidence and scientific strategy
- Partner with Clinical Development, Biostatistics, Regulatory, and Commercial to define and execute an integrated evidence generation plan beyond the registrational study to address potential evidence gaps and strategic priorities
- Serve as a key scientific partner in shaping development strategy, trial design, endpoints, and data interpretation
- Ensure alignment between clinical data, scientific communication, and external stakeholder needs
Engage the external ecosystem
- Build and deploy a field medical organization capable of high-quality, peer-to-peer scientific exchange
- Provide executive leadership, in partnership with Commercial Operations and IT, for the strategy, development, and governance of MSL field enablement capabilities, including CRM platform, medical analytics, leadership dashboards, and MLR review
- Build trusted relationships with KOLs, treatment centers, and patient advocacy groups
- Represent Immix in advisory boards, scientific forums, and external collaborations
- Bring external insights back into the organization to inform strategy and decision-making
What We Look For
Education & Experience
- Advanced degree preferred (MD, PhD, PharmD, or equivalent preferred)
- 3-5+ years experience in the biopharmaceutical industry with focus in hematology/oncology; experience in plasma cell disorders strongly preferred
- Medical Affairs leadership with demonstrated success building and leading teams
- Familiarity with complex and composite clinical endpoints (MRD, CHR) strongly preferred
- Proven experience supporting or leading a product launch; cell and/or gene therapy launch experience a plus
- Experience in small or emerging biotech environments a plus; experience supporting breakthrough-designated, accelerated approval and/or single-arm registrational programs a plus
Capabilities
- Deep scientific and clinical acumen, with the ability to engage credibly at the highest levels of the medical community
- Strategic mindset with the ability to identify key decisions, frame trade-offs, and guide cross-functional alignment
- Ability to translate complex data into a clear, compelling, and credible scientific narrative
- Demonstrated ability to operate effectively in ambiguous, fast-paced environments
- Strong leadership and team-building capabilities with a commitment to developing others
- Excellent communication skills, with the ability to influence internal and external stakeholders, including experience with C-suite and Board executive leadership
Distinctive Strengths
- Equally comfortable in deep scientific exchange and executive-level strategic dialogue
- Able to translate complex data into a compelling narrative for diverse stakeholders
- High degree of initiative, intellectual curiosity, and ownership
- Collaborative, low-ego leader who can work across functions to achieve shared goals
Location & Travel
- US-based, remote
- Ability to travel approximately 30–50% as required
About Immix Biopharma
Immix Biopharma is committed to harnessing the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting. Our lead asset, NXC-201, is a differentiated BCMA-directed CAR-T therapy being developed for relapsed/refractory AL amyloidosis—an area of critical unmet need. We are advancing rapidly toward potential approval and launch, with the goal of bringing a transformative therapy to patients.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
